ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0025

Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 0414

Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0084

Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0359

Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0409

Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0218

Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0180

Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0343

Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0013

Colchicine to Weather the Storm in Hospitalized Patients with COVID-19

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0355

Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0368

Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0333

Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0334

Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0324

Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0403

Comparison of Immediate Post-Operative and Long-Term Outcomes in Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

«Previous Page
1
…
4
5
6
7
8
…
35
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].